Equity Profile

CRMD

CorMedix Inc.

Health CarePharmaceuticals$632.1M

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

CorMedix Inc. is a pharmaceutical company focused on developing and commercializing innovative therapeutic products for patients with serious medical conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.43

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and increase sales, which is crucial for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CRMD Q2-2026 Earnings Preview

Context

Company Snapshot

CorMedix Inc. is a pharmaceutical company focused on developing and commercializing innovative therapeutic products for patients with serious medical conditions. Operating in the health care sector, its work is particularly relevant as the demand for effective treatments continues to grow, especially in areas like infection prevention and chronic disease management.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+37.26%

Avg Stock Reaction

-1.74%

Last Quarter Recap

In Q1 2026, CorMedix reported an EPS of $0.43, surpassing estimates by 24.64%. The stock reacted positively, gaining 5.73% the following day.

Management Promises & Guidance

Continued focus on expanding product offerings.
Commitment to improving operational efficiencies.
Plans to enhance marketing strategies to boost sales.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about CorMedix's upcoming earnings report, especially after a strong performance last quarter.

Bull Case

If CorMedix can maintain or exceed its EPS from last quarter, it could signal robust growth and investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, reflecting investor disappointment.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.43

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

N/A

Revenue growth reflects the company's ability to expand its market presence and increase sales, which is crucial for long-term success.

Market Reaction to Earnings

N/A

Understanding how the stock typically reacts to earnings surprises can provide insight into investor sentiment and market expectations.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will CorMedix maintain or exceed the EPS of $0.43 from last quarter?

This number is crucial for demonstrating consistent profitability and could significantly influence investor sentiment.

What guidance will management provide regarding future revenue growth?

Investors will be looking for clarity on the company's growth trajectory, which is essential for long-term confidence in the stock.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating CorMedix's ability to maintain its recent earnings momentum, particularly given its strong performance last quarter.

Supporting Evidence

The company's EPS surprise of +24.64% last quarter suggests robust operational performance.

Options pricing indicates a significant expected move, reflecting heightened investor interest.

The historical EPS beat rate of 88% indicates a strong track record of exceeding expectations.

Key Risk

If the EPS comes in below $0.35, it could challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is currently weighing the company's ability to sustain its recent earnings momentum against potential challenges in revenue growth.

Bull Confirmed If

An EPS of $0.45 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.35 would support the bear case, suggesting potential issues in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±22.51%

Historical Avg

±17.1%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings announcement.

Options are pricing ±22.5% while CRMD has averaged ±17.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

43.4%

Calls (50K)P/C Ratio: 0.11Puts (2K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CorMedix beats expectations, history suggests the stock could rise by around 2.89% on the first day, confirming positive momentum.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors assess management's commentary.

Miss

If the company misses estimates, history indicates a potential decline of around 11.52%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on market conditions and competitive landscape.
3Insights into operational efficiencies and cost management strategies.
4Guidance on revenue expectations for the upcoming quarters.
5Responses to analyst questions regarding potential risks or challenges.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

CorMedix Inc. is a pharmaceutical company focused on developing and commercializing innovative therapeutic products for patients with serious medical conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.43

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and increase sales, which is crucial for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CRMD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+37.26%

Avg Stock Reaction

-1.74%

Last Quarter Recap

In Q1 2026, CorMedix reported an EPS of $0.43, surpassing estimates by 24.64%. The stock reacted positively, gaining 5.73% the following day.

Management Promises & Guidance

Continued focus on expanding product offerings.
Commitment to improving operational efficiencies.
Plans to enhance marketing strategies to boost sales.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about CorMedix's upcoming earnings report, especially after a strong performance last quarter.

Bull Case

If CorMedix can maintain or exceed its EPS from last quarter, it could signal robust growth and investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, reflecting investor disappointment.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.43

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

N/A

Revenue growth reflects the company's ability to expand its market presence and increase sales, which is crucial for long-term success.

Market Reaction to Earnings

N/A

Understanding how the stock typically reacts to earnings surprises can provide insight into investor sentiment and market expectations.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will CorMedix maintain or exceed the EPS of $0.43 from last quarter?

This number is crucial for demonstrating consistent profitability and could significantly influence investor sentiment.

What guidance will management provide regarding future revenue growth?

Investors will be looking for clarity on the company's growth trajectory, which is essential for long-term confidence in the stock.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating CorMedix's ability to maintain its recent earnings momentum, particularly given its strong performance last quarter.

Supporting Evidence

The company's EPS surprise of +24.64% last quarter suggests robust operational performance.

Options pricing indicates a significant expected move, reflecting heightened investor interest.

The historical EPS beat rate of 88% indicates a strong track record of exceeding expectations.

Key Risk

If the EPS comes in below $0.35, it could challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is currently weighing the company's ability to sustain its recent earnings momentum against potential challenges in revenue growth.

Bull Confirmed If

An EPS of $0.45 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.35 would support the bear case, suggesting potential issues in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±22.51%

Historical Avg

±17.1%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings announcement.

Options are pricing ±22.5% while CRMD has averaged ±17.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

43.4%

Calls (50K)P/C Ratio: 0.11Puts (2K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CorMedix beats expectations, history suggests the stock could rise by around 2.89% on the first day, confirming positive momentum.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors assess management's commentary.

Miss

If the company misses estimates, history indicates a potential decline of around 11.52%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on market conditions and competitive landscape.
3Insights into operational efficiencies and cost management strategies.
4Guidance on revenue expectations for the upcoming quarters.
5Responses to analyst questions regarding potential risks or challenges.